PDB89 Assessing Quality of Life in Adult Growth Hormone Deficiency: Further Development of the QoL-AGHDA  by Graham, J.E. et al.
A446  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
PDB87
The DiaBeTic PeriPheral NeuroPaThic PaiN imPacT (DPNPi) measure 
– PsychomeTric ValiDaTioN of a New PaTieNT rePorTeD ouTcome 
measure
Brod M.1, Ramasamy A.2, Bushnell D.M.3, Blum S.I.2
1The Brod Group, Mill Valley, CA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Health 
Research Associates, Inc., Seattle, WA, USA
Objectives: The Diabetic Peripheral Neuropathic Pain Impact (DPNPI) Measure is a 
patient-reported outcome (PRO) measure developed in accordance with the FDA PRO 
guidance for assessing the impacts of living with Diabetic Peripheral Neuropathic 
Pain (DPNP). A validation study was conducted to evaluate the measurement model 
and properties of the 27-item draft version of the DPNPI. MethOds: A non-inter-
ventional, observational, survey-based validation study enrolled outpatients from 
clinical sites in the United States. Recruitment included diagnosed DPNP patients 
(aged 18-80) both treated and untreated with prescription agents. Subjects com-
pleted a retest survey via mail two weeks after their in-clinic assessment. Analyses 
included assessment of the measurement model (factor analysis), reliability (inter-
nal consistency, test-retest) and validity (content, known-groups) of the DPNPI. IRT 
was utilized to evaluate item fit and function. Results: Out of 124 subjects (56% 
male, mean age 62.8),105 completed the retest survey. Nine items from the draft 
version were deleted due to conceptual issues and/or redundancy. Factor analysis 
confirmed the three hypothesized domains: Physical/Mobility Function; Daily Life; 
Sleep. All domains and the total score were internally consistent (0.91 to 0.96) and 
reproducible (0.84 to 0.91). All a priori convergent validity hypotheses were confirmed 
(p< .001) with moderate-strong association between the total and/or subscale scores 
on the DPNPI measure and other logically related measures (range 0.43 to 0.79). 
Additionally, all a priori hypothesized associations for content and known-group 
validity of domains and total score were confirmed (p< .001) and IRT fit statistics 
were within acceptable range. cOnclusiOns: The final 18-item version of the 
DPNPI can be considered a well-designed, valid and reliable measure of the impact 
of DPNP on patients’ daily lives and physical functioning. This measure can be used 
as an endpoint in clinical trials to assess impacts related to DPNP. Further study is 
needed to understand the responsiveness of the DPNPI.
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how hyPoglycemia imPacTs QualiTy of life aND TreaTmeNT 
saTisfacTioN iN TyPe 2 DiaBeTes melliTus PaTieNTs oN Basal-Bolus 
iNsuliN TheraPy?
Ionova T.I.1, Odin V.I.2, Nikitina T.P.1, Kurbatova K.A.1, Shablovskaya N.E.1
1Multinational Center for Quality of Life Research, Saint-Petersburg, Russia, 2Military Medical 
Academy, Saint-Petersburg, Russia
Objectives: Hypoglycemia burden is the most common problem in patients with 
type 2 diabetes mellitus (T2DM) receiving insulin treatment. However, how hypogly-
cemia affects quality of life (QoL) and treatment satisfaction in this patient popula-
tion is less clear. We aimed to study the QoL and treatment satisfaction in T2DM 
patients on basal-bolus insulin therapy with the absence and presence of different 
types of hypoglycemia. MethOds: A total of 500 T2DM patients receiving basal-
bolus insulin therapy for at least 6 months were enrolled in the survey: male/female 
122/378; mean (SD) age 61.8 (8.4) yrs; mean (SD) time from T2DM diagnosis 12.8 (6.9) 
yrs. Mean HbA1c level was 8.3%. Patients were classified as with no, non-severe, 
severe and nocturnal hypoglycemia events during the last month. Patients filled 
out SF-36 and Patient Treatment Satisfaction Questionnaire. The impact of hypo-
glycemia on QoL and treatment satisfaction was examined through multivariate 
regression, adjusting for sociodemographics and disease status. QoL and treatment 
satisfaction scores were analyzed using t-test, ANOVA, Chi-square test. Results: 
After adjustment, QoL and treatment satisfaction decreased with the increase of 
hypoglycemia events (p< 0.05). Patients with hypoglycemia had significantly lower 
QoL scores for 6 out of 8 SF-36 scales as compared to those without hypoglyce-
mia (p< 0.05). Treatment satisfaction was higher in patients without hypoglycemia 
than in those with hypoglycemia (mean score 7.25 vs 8.0; p= 0.01). Patients with 
nocturnal and severe hypoglycemia had significant reduction of role-physical, 
social functioning, vitality and pain as compared to patients with non-severe 
hypoglycemia (p< 0.05). The percentage of patients who were completely dissatis-
fied or poorly satisfied with treatment was higher in the group with severe or/and 
nocturnal hypoglycemia than in those with non-severe hypoglycemia (20% vs 8%; 
p= 0.002). cOnclusiOns: Hypoglycemia has negative impact on QoL and treatment 
satisfaction in T2DM patients. Severe and nocturnal hypoglycemia significantly 
decreases QoL and reduces treatment satisfaction.
PDB89
assessiNg QualiTy of life iN aDulT growTh hormoNe DeficieNcy: 
furTher DeVeloPmeNT of The Qol-aghDa
Graham J.E., McKenna S., Wilburn J., Twiss J.
Galen Research Ltd., Manchester, UK
Objectives: The QoL-AGHDA assesses quality of life (QoL) specific to adults with 
Growth Hormone Deficiency (GHD). Questionnaire content was derived from quali-
tative interviews conducted with individuals who had the condition. Since its devel-
opment a number of new language adaptations have been made for Europe (9), 
Eastern Europe (4), and Central and South America (2). New language versions of 
the measure were required for use in two major new multinational clinical trials. 
These were for Greece, Hungary, Israel, Romania, Russia, Slovakia, Ukraine and the 
US (Spanish). MethOds: The dual-panel methodology was employed to translate 
each of these measures. This approach has been used in the adaptation of all needs-
based QoL measures. Two panels are held. The first employs local people who are 
also proficient in English who agree the most appropriate translation for the instruc-
tions and items. The second panel involves lay people who ensure that the level of 
language is appropriate and will be understood by future respondents. Following 
translation, cognitive debriefing interviews were conducted with adults with GHD 
in each country. Results: No major difficulties were experienced in producing 
Objectives: Foot ulceration is a major cause of disability in diabetes. The aim 
of this study was to estimate influence of severity of diabetic foot ulceration on 
HRQoL. MethOds: A survey among DFS (Diabetic Foot Syndrome) patients with 
active foot ulceration treated in ambulatory care was conducted. The PEDIS scale 
was used to classify severity of ulceration. To assess the impact of diabetic ulcera-
tion on HRQoL in DFS patients the EQ-5D-3L questionnaire was used. Utility scores 
were calculated based on Polish EQ-5D value set (Golicki et al.) Results: Between 
April 2012 and May 2013 185 patients were questioned directly. 179 of them (131 
males) completed the EQ-5D questionnaire and had full record on ulceration sever-
ity (the PEDIS scale). The mean age of patients was 61.9±10.6 years. Diabetes type 
2 was diagnosed in 150 (83.8%) patients while diabetes type 1 in 26 (14.5%). Other 
type of diabetes was diagnosed in 2 persons and data on one were missing. Mean 
time from the diagnosis of diabetes was 18.0±11.1 years. 99 (55%) and 69 (39%) 
patients had grade 1 and 2 perfusion, respectively. The mean ulceration size was 
6.2±13.4 cm2. 74 (41.3%), 65 (36.3%) and 40 (22.3%) patients had grade 1, 2 and 3 
depth/tissue loss respectively. 84 (46.9%), 55 (30.7%) and 36 (20.1%) patients had 
grade 1, 2 and 3 infection, respectively. Most patients (89.4%) had loss of protective 
sensation (grade 2 sensation). Mean utility value in overall population was esti-
mated at 0.618±0.320. Very week negative correlation was found between ulcera-
tion size and utility value. Despite some differences in utility value in patients 
with different perfusion grade no strict correlations between severity of ulceration 
and utility values were found. cOnclusiOns: There is little or no strict correla-
tion between severity of ulceration measured with the PEDIS scale and HRQoL 
measured with the EQ-5D.
PDB85
DiaBeTic PaTieNTs iN Primary care: self-PercePTioN aND saTisfacTioN. 
comParaTiVe sTuDy sPaiN Versus euroPe
Sánchez-Piedra C., García-Pérez S., Sarría S.antamera A
Agencia de Evaluación de Tecnologías Sanitarias (AETS), Madrid, Spain
Objectives: EUprimecare is an European Union project aimed at analyzing the 
costs and quality of the different models of primary care (PC) in Europe. The aim 
of this study is to analyze the management of diabetic patients in PC services in 
Spain compared to other European countries, the satisfaction of these patients 
with PC services and their self-perceived health status. MethOds: We conducted 
a population survey by telephone among PC users in each of the consortium 
countries (Germany, Spain, Estonia, Finland, Hungary, Italy and Lithuania). The 
questionnaire included information on sociodemographic characteristics, health 
status, satisfaction, utilization of PC services, and frequency of some interven-
tions carried out by PC professionals. The survey was conducted to 431-432 PC 
users in each country (Ntotal = 3020). Results: The percentage of diabetic 
patients in Spain was 6.7% (N = 29), lower than the overall average (9.1%). Eighty 
three percent of patients living in Spain were diagnosed by their PC physicians 
compared with 73% of the European average. Eighty six percent of patients in 
Spain said that they were being treated for diabetes (EU average = 84%) and in 
88% of these cases the treatment was prescribed by their PC doctor (EU average 
= 70%). Only 6.9% of patients said their health was poor or very poor, the lowest 
proportion of all countries assessed. The overall satisfaction with PC services 
among diabetic patients was 4.10 points on a scale of 1 to 5. Satisfaction in Spain 
was below the global average for all the items measured. cOnclusiOns: Diabetic 
patients in Spain are more frequently controlled by PC professionals than in 
other European countries. These patients have a better self-perceived health 
status and the results of this study suggest a lower level of dissatisfaction with 
the services provided by PC.
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PaTieNTs PrefereNces regarDiNg The TreaTmeNT of TyPe ii DiaBeTes 
melliTus: comParisoN of BesT-worsT scaliNg aND aNalyTic 
hierarchy Process
Mühlbacher A.C., Bethge S., Kaczynski A., Juhnke C.
Hochschule Neubrandenburg, Neubrandenburg, Germany
Objectives: There is limited evidence available regarding patient preferences 
for treatment alternatives, including those treatment characteristics that have 
greatest influence on the perceived value, and how this knowledge can be used 
in health care decision-making. The objective of this study was to identify and 
elicit patient preferences for treatments in Type-II-Diabetes in different patient 
groups. MethOds: In order to elicit patient preferences this study used an 
explorative qualitative approach in combination with quantitative survey tech-
niques. Literature research and semi-structured interviews (N= 15) were the basis 
of quantitative elicitations (N= 388) using Analytic-Hierarchy-Process (AHP) and 
Best-Worst-Scaling (BWS). The study aimed at the determination of the relative 
importance of patient-relevant decision criteria as well as to compare two meth-
ods of measuring preference. In total, seven therapy-related attributes (three lev-
els each) were tested. The sample contained patients receiving oral anti-diabetics 
(OAD) (N= 200) or insulin (N= 188). Results: The qualitative study identified 22 
patient-relevant treatment-characteristics. Out of these the seven most impor-
tant were included in AHP and BWS. The AHP- as well as BWS-surveys resulted in 
a dominance of the attribute “HbA1c-Level”, for both OAD- and Insulin-patients. 
In the OAD-group AHP and BWS independently showed the same ranking of the 
three attributes: “Delay of Insulin-Therapy” (Rank 2), “Occurrence of hypoglyce-
mia” (Rank 3) and “Weight changes” (Rank 4). In the Insulin-group “Occurrence 
of hypoglycemia” was ranked second using AHP and third within BWS. “Weight 
changes” were ranked equally in both methods. However their relevance among 
different patient groups changed. cOnclusiOns: In both patient-groups AHP 
and BWS show similar results. Nonetheless both groups have different horizons 
of experience and differ in the ranking of decision criteria. For the first time the 
methods of AHP and BWS were used to assess patients’ preferences for different 
characteristics of treatment in Type-II-Diabetes, as well as the influence of those 
criteria on the patient benefit.
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Objectives: Acromegaly is a rare, chronic, hormonal disorder caused by excessive 
growth hormone (GH) and insulin-like growth factor 1 (IGF-1) production resulting 
predominantly from pituitary adenoma. The objective was to test endocrinologist 
acceptability of the newly developed SAGIT tool in clinical practice. MethOds: 
SAGIT (signs and symptoms - associated comorbidities - gH concentration level 
– iGF-1 – Tumour) is a Clinician-Reported Outcomes (ClinROs) tool developed with 
international experts in acromegaly; it allows patient classification and descrip-
tion in a standardised manner. The tool was pre-tested for acceptability, under-
standing and ease of use with practicing endocrinologists in France, Germany, UK, 
Spain, Italy and Brazil (n= 2 per country) using the PRAgmatic Content and face 
validity Test (PRAC-Test). The endocrinologists completed the SAGIT tool prior to 
and following an intervention (therapeutics or surgery) for three patients each 
(n= 36). Once completed, a one-hour phone interview was conducted with each 
endocrinologist to collect their feedback on the tool. Results: The tool was well 
accepted and deemed concise (n= 11) and informative (n= 10) by the endocrinolo-
gists. Several points were raised that illustrate its usefulness in clinical practice, 
including the removal of the subjectivity when assessing the disease severity, the 
possibility of rapid evaluation of the control/progression of acromegaly or of a 
treatment response, and the possibility for standardisation across countries. Key 
recommendations for improvements were the need to include: 1) instructions to 
facilitate the understanding and the use of the tool; 2) definitions of rules and 
recommendations for patient management; and 3) addition of other signs and 
symptoms and further details about tumour size to better reflect their clinical 
cases. cOnclusiOns: SAGIT is a useful tool for endocrinologists to accurately 
stage and classify acromegaly patients in clinical practice. It is currently being 
piloted in a cross-sectional study. Validation of scoring rules will confirm the utility 
of the tool to improve patient management.
PDB93
a DiscreTe choice exPerimeNT To eValuaTe BlooD glucose meTer 
PrefereNces iN PeoPle wiTh TyPe 1 aND TyPe 2 DiaBeTes iN The uNiTeD 
KiNgDom
Perard R.1, Orme M.E.2
1Montpellier University, Montpellier, France, 2ICERA Consulting Ltd., Swindon, UK
Objectives: Regular self-monitoring of using a blood glucose meter helps diabetic 
patients to adjust their management strategies proactively, thus avoiding diabetic 
complications which place a burden on health care resources. The aim of this study 
was to elicit diabetic patients’ preferences for different blood glucose meter attrib-
utes. MethOds: A cross-sectional, web-based survey of UK patients with Type 1 and 
type 2 diabetes was conducted in January 2013 and preferences for five key attributes 
associated with blood glucose meters were estimated using a discrete choice experi-
ment (DCE) framework. A foldover design and optimised orthogonal differences 
were considered, but the final choice experiment was a Bayesian d-efficient design. 
Responses were analysed using a conditional logit model in STATA 12.1. Results: 
Out of 447 responses, 406 (90.83%) patients were suitable for inclusion in the DCE 
analysis. Statistically significant differences (p< 0.05) were found between the Type 1 
and Type 2 sub-groups when comparing responder characteristics (years diagnosed, 
age, tests per day, number of comorbidities). Regarding glucose meter attributes, 
Type 1 respondents considered the ‘time to test’ to be the most critical factor and 
were willing to trade a compact device (2.61 units), or convenience (1.37 units) for 
a device that could produce test results in under 30 seconds. Type 2 respondents 
preferred the low maintenance attribute and were most willing to trade a compact 
device (2.72 units) or convenience (1.37 units) for this attribute. cOnclusiOns: This 
is the first DCE to examine the impact of blood glucose meter attributes on blood 
glucose meter choice and adherence. Devices that provide value added features such 
as offline storage of data and additional data analysis will be valued by both Type 1 
and Type 2 patients whereas a compact device is less valued.
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growTh mixTure moDeliNg (gmm) To DeTermiNe TreaTmeNT effecTs of 
caNaglifloziN Versus siTagliPTiN oN weighT-relaTeD QualiTy of life 
(wrQol) iN suBjecTs wiTh TyPe 2 DiaBeTes melliTus (T2Dm)
Stull D.E.1, Houghton K.1, Traina S.B.2
1RTI Health Solutions, Didsbury, Manchester, UK, 2Janssen Global Services, LLC, Raritan, NJ, USA
Objectives: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed 
for T2DM. GMM was used to evaluate the effects of canagliflozin versus sitaglip-
tin on WRQoL in subjects with T2DM. MethOds: Data were from 2 multinational, 
randomised, double-blind, Phase 3 trials: 1) subjects inadequately controlled with 
metformin (N= 1,284) receiving canagliflozin 100 or 300 mg, sitagliptin 100 mg, or 
placebo for 26 weeks with a 26-week extension (placebo switched to sitagliptin; 
dual therapy); and 2) subjects inadequately controlled with metformin plus a sul-
phonylurea (N= 755) receiving canagliflozin 300 mg or SITA 100 mg for 52 weeks 
(triple therapy). WRQoL was assessed using the Impact of Weight on Quality of 
Life-Lite (IWQOL-Lite) questionnaire. GMM was used to assess heterogeneity within 
samples to identify data-driven subgroups with differential changes in IWQOL-Lite 
total scores. Results: In both trials, GMM identified 2 subgroups per treatment 
arm: “subgroup 1” (81% and 87% of total trial samples) started with high scores 
(~85 points), while “subgroup 2” (19% and 13% of total trial samples) started with 
low scores (44-53 points). Subgroup 1 scores remained high throughout both tri-
als for all treatments. For the dual-therapy trial, subgroup 2 subjects treated with 
canagliflozin 100 or 300 mg had improvement (2.1 and 5.4 points, respectively), 
while those treated with sitagliptin 100 mg had declining scores (–4.0 points) over 
the course of the trial (P < 0.05). For the triple therapy trial, all subgroup 2 subjects 
improved; improvement was significantly greater with canagliflozin 300 mg versus 
sitagliptin 100 mg (19.6 vs 4.8 points; P< 0.05). In both trials, there were significant 
differences between the subgroups based upon baseline demographic, clinical, and 
patient-reported characteristics. cOnclusiOns: GMM applied to these trial data 
enabled identification of treatment effects that were masked by standard statisti-
cal techniques. Heterogeneity should be considered when analysing WRQoL data.
the translations. Ten to fifteen cognitive debriefing interviews were conducted 
in each country. Interviewees reported the measure to be easy to understand 
and complete and that the content was relevant without missing important 
issues. cOnclusiOns: The standards set by the existing UK version of the QoL-
AGHDA are high with internal consistency and test-retest reliability above 0.90. 
Construct validity was also demonstrated by the measure’s ability to distinguish 
between patients according to self-perceived general health and by correlating 
scores with those on the General Well Being Index (> 0.70). Completed validations 
have obtained a similar psychometric quality. Similar studies are underway to evalu-
ate the formal construct validity and reproducibility of these new language versions.
PDB90
usefulNess of The hyPoglycemia PersPecTiVes QuesTioNNaire (hPQ) iN 
maNagemeNT of PaTieNTs wiTh TyPe 2 DiaBeTes
Ionova T.I., Nikitina T.P., Kurbatova K.A., Shablovskaya N.E.
Multinational Center for Quality of Life Research, Saint-Petersburg, Russia
Objectives: Assessment of patient’s perspectives of hypoglycemia burden may 
be of value to provide adequate management of type 2 diabetes (T2D) patients. 
The Hypoglycemia Perspectives Questionnaire (HPQ) is a new multidimensional 
instrument assessing patient’s experience of hypoglycemia. The goal of this study 
was to test the practicability and utility of HPQ-Russian version (HPQ-R) by means 
of its psychometric performance. MethOds: A total of 200 T2D patients receiving 
oral hypoglycemic therapy (59% – metformin; 41% – metformin plus vildagliptin or 
sulphonylureas, SU) were enrolled in the study: male/female 71/129; mean age – 
58.7 yrs; mean disease duration – 4.1 yrs. Mean HbA1c level was 7%. All the patients 
completed HPQ-R at baseline and after 2-3 months of treatment. Patients and physi-
cians were interviewed to test practicability of the instrument. Construct validity, 
reliability and sensitivity of the HPQ-R were assessed to provide its utility. Results: 
Both patients and physicians acknowledged the comprehensiveness of the tool for 
revealing hypoglycemia-related problems; physicians used information from it for 
their decision-making. It was easily understood by, and administered to patients: 
2.8% of missing values. An exploratory factor analysis revealed a strongly dimen-
sional instrument (explained 70% of total pooled variance), with Chronbach alphas 
≥ 0.9 for 6 out of 7 scales. Reproducibility of the tool was shown by comparing 
HPQ-R scores at two time-points for patients with effective HbA1c control receiving 
metformin plus vildagliptin: r= 0.53–0.87 for 5 scales (p< 0.05). HPQ-R scores were 
lower in patients with hypoglycemia events than in patients without hypoglycemia 
as well as in patients with severe hypoglycemia than in patients with non-severe 
hypoglycemia (p< 0.05). Increased occurrence of hypoglycemia events and worsening 
of scores for 4 HPQ scales was shown after switch from monotherapy to therapy 
metformin plus SU (p< 0.05). cOnclusiOns: Thus, the HPQ-R is a practical and use-
ful tool for comprehensive assessment of hypoglycemia experience in T2D patients.
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BeNefiTs of VilDagliPTiN Plus meTformiN comBiNaTioN TheraPy iN 
TyPe 2 DiaBeTes melliTus (T2Dm) from PaTieNT’s PersPecTiVe: QualiTy 
of life (Qol) aND hyPoglycemia BurDeN aNalysis
Ionova T.I.1, Odin V.I.2, Nikitina T.P.1, Kurbatova K.A.1, Shablovskaya N.E.1
1Multinational Center for Quality of Life Research, Saint-Petersburg, Russia, 2Military Medical 
Academy, Saint-Petersburg, Russia
Objectives: Patients’ preferences and evaluation of treatment benefits/risks from 
patient’s perspective are increasingly being considered in decision-making regard-
ing treatment option. The goal of this prospective, open, observational study was to 
evaluate QoL and hypoglycemia burden in T2DM patients treated with vildagliptin 
and metformin as compared to those treated with sulphonylureas (SU) and met-
formin. MethOds: A total of 194 T2DM patients previously on oral monotherapy 
were enrolled in the study. 111 patients were selected by their treating physician to 
receive vildagliptin and metformin (cohort 1 – mean age 58 yrs; male/female 43/68) 
and 83 patients – SU and metformin (cohort 2– mean age 58.6 yrs; male/female 
27/56). Patient-reported outcomes were assessed at base-line and after approxi-
mately 3 mo using the SF-36 and the Hypoglycemia Perspectives Questionnaire 
(HPQ). For comparisons adjustment for age, sex, disease duration, complications 
and comorbidities was made. Results: QoL parameters for all SF-36 scales were 
significantly higher in cohort 1 as compared to cohort 2 after 3 mo of therapy 
(p< 0.01). Switch to vildagliptin plus metformin therapy was accompanied with 
remarkable increase of Integral QoL Index (p< 0.0001) whereas no changes of 
Integral QoL Index were observed after switch to SU plus metformin. After 3 mo 
of combination therapy the number of self-reported symptomatic hypoglycemic 
events was 16% in cohort 1 versus 70% in cohort 2; 12% of pts had severe hypogly-
cemic events in cohort 2. SU plus metformin therapy was accompanied with sig-
nificant hypoglycemia burden – after switching worries, awareness and symptom 
concern increased (p< 0.001). No changes were observed in cohort 1. The changes 
in glycemic control were the same in both cohorts: DHbA1c= 0.8%. cOnclusiOns: 
Benefits of vildagliptin plus metformin combination therapy in terms of improved 
QoL and reduced hypoglycemia burden in T2DM patients were shown. This therapy 
is an effective and preferable treatment in daily medical practice from patient’s 
perspective.
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PrelimiNary TesTiNg of The sagiT Tool: a Tool To helP 
eNDocriNologisTs iN Their maNagemeNT of PaTieNTs wiTh 
acromegaly iN cliNical PracTice
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